Earnings call briefThird-quarter 2026
AbbVie raises 2026 revenue forecast to about $67.8 billion
AbbVie said it now expects immunology sales of $34.9 billion and neuroscience revenue of $13 billion.
GetSignal AbbVie ABBV
AbbVie said on its third-quarter call that it now expects 2026 total net revenues of approximately $67.8 billion, an increase of $200 million. It said it expects fourth-quarter net revenues of approximately $18.4 billion and adjusted earnings per share of $3.83 to $3.87, and that the fourth-quarter outlook excludes acquired IPR&D expense for the quarter.
Quotes from the call
“We now expect total net revenues of approximately $67.8 billion, an increase of $200 million.”
Key facts from the call
- 2026 net revenue outlook
- Approximately $67.8 billion, an increase of $200 million
- Expected fourth-quarter net revenues
- Approximately $18.4 billion
- Expected fourth-quarter adjusted EPS
- $3.83 to $3.87
Source: AbbVie's third-quarter 2026 earnings call, October 30, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
- TeraWulf sees about half of contracted IT capacity earning revenue by end of Q1
WULF TeraWulf Q3 2026 call
